Clinical Trial

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Enrollment increased: 8 -> 9 participants 2026-07-31
notable Primary completion pushed: 2026-05 -> 2026-08 2026-07-31
minor Completion pushed: 2026-05 -> 2026-09 2026-07-31
Trial Details
NCT Number NCT06947304
Lead Sponsor Corcept Therapeutics
Collaborators: University of Missouri-Columbia
Conditions Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Enrollment 9 participants
Start Date 2025-08-22
Primary Completion 2026-08 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-30